Role of ADH5 in the Regulation of Brown Adipose Tissue Metabolic Homeostasis

ADH5 在棕色脂肪组织代谢稳态调节中的作用

基本信息

  • 批准号:
    10684223
  • 负责人:
  • 金额:
    $ 49.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-19 至 2026-07-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Dysregulated metabolic function and chronic inflammation are prominent features of obesity in both humans and animal models. Brown adipose tissue (BAT) plays a critical role in metabolic adaptation in response to stresses including overnutrition, wherein the metabolic adaptation is disrupted and inflammatory stress is elevated. However, there remains a key knowledge gap in the interplay between inflammatory and metabolic cues in BAT during overnutrition. Obesity-associated chronic inflammation is characterized by excessive nitric oxide (NO) production and aberrant protein cysteine nitrosylation (S-nitrosylation). Our preliminary data showed that diet- induced obesity (DIO) elevates BAT protein S-nitrosylation, including uncoupling protein 1 (UCP1). This aberrant BAT NO bioactivity is in part due to downregulation of alcohol dehydrogenase 5 (ADH5), the major denitrosylase modulating cellular nitro-thio redox balance. Moreover, we showed that BAT Adh5 deletion suppressed UCP1- dependent mitochondrial respiration, worsened glucose intolerance and increased BAT inflammation in mice with DIO. All of these defects were improved by restoration of Adh5 expression in the BAT. These data provide the first evidence that ADH5 plays a protective role in the BAT against metabolic stress. Thus, we hypothesize obesity compromises ADH5-regulated cellular nitrosative homeostasis in the thermogenic adipose tissue, contributing to obesity-associated metabolic dysfunction. We will test this hypothesis by completing two specific aims. In Aim 1, we will define the mechanism by which obesity suppresses ADH5 expression and its pathophysiological significance in obesity. In Aim 2, we will determine the molecular mechanisms underlying ADH5-mediated BAT metabolic homeostasis. The regulation of BAT metabolic function by nitro-redox signaling and the contribution of this regulation to metabolic dysfunction in obesity are new and unexplored concepts. Accomplishment of this project will provide first insights into the mechanisms by which aberrant NO signaling links BAT inflammatory cues to metabolic dysfunction and new avenues for developing of therapeutic targets to ameliorate BAT dysfunction in the context of obesity.
项目总结 代谢功能失调和慢性炎症是人类和 动物模型。棕色脂肪组织(BAT)在应激反应的代谢适应中起着关键作用 包括营养过剩,代谢适应被扰乱,炎性应激加剧。 然而,在BAT的炎症和代谢信号之间的相互作用方面,仍然存在一个关键的知识差距。 在营养过剩的时候。肥胖相关的慢性炎症以过量的一氧化氮(NO)为特征 生产和异常蛋白半胱氨酸亚硝化(S亚硝化)。我们的初步数据显示,节食- 诱导肥胖使包括解偶联蛋白1(UCP1)在内的BAT蛋白S-亚硝化水平升高。这种反常现象 BAT没有生物活性的部分原因是主要的脱氮酶乙醇脱氢酶5(ADH5)的下调 调节细胞硝基-硫代氧化还原平衡。此外,我们还发现BAT Adh5的缺失抑制了UCP1- 小鼠依赖线粒体呼吸、加重糖耐量和增加BAT炎症 使用DIO。通过恢复Adh5在BAT中的表达,所有这些缺陷都得到了改善。这些数据提供了 首次有证据表明ADH5对蝙蝠的代谢应激具有保护作用。因此,我们假设 肥胖损害了ADH5调节的生热脂肪组织中的细胞亚硝酸盐稳态, 导致肥胖相关的代谢功能障碍。我们将通过完成两个特定的项目来验证这一假设 目标。在目标1中,我们将定义肥胖抑制ADH5表达的机制及其 肥胖的病理生理学意义。在目标2中,我们将确定潜在的分子机制 ADH5介导的BAT代谢动态平衡硝基氧化还原信号对BAT代谢功能的调节 而这种调节对肥胖症代谢功能障碍的贡献是新的和未被探索的概念。 该项目的完成将提供对异常NO信号转导机制的初步见解 将BAT炎症信号与代谢功能障碍联系起来,并为开发治疗靶点提供新途径 改善肥胖背景下的蝙蝠功能障碍。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ling Yang其他文献

Ling Yang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ling Yang', 18)}}的其他基金

Regulation and Function of Thioredoxin Interacting Protein (Txnip) in Nonalcoholic Steatohepatitis (NASH)
硫氧还蛋白相互作用蛋白 (Txnip) 在非酒精性脂肪性肝炎 (NASH) 中的调节和功能
  • 批准号:
    10736673
  • 财政年份:
    2023
  • 资助金额:
    $ 49.74万
  • 项目类别:
Identification and Characterization of Novel Metabolic Regulators in Mouse and Human Liver
小鼠和人类肝脏中新型代谢调节剂的鉴定和表征
  • 批准号:
    9762204
  • 财政年份:
    2018
  • 资助金额:
    $ 49.74万
  • 项目类别:
Integration of Inflammatory Signaling and the Unfolded Protein Response by Nitrosylation Signaling in Obesity
肥胖中炎症信号传导与亚硝基化信号传导的未折叠蛋白反应的整合
  • 批准号:
    10302313
  • 财政年份:
    2017
  • 资助金额:
    $ 49.74万
  • 项目类别:
Integration of Inflammatory Signaling and the Unfolded Protein Response by Nitrosylation Signaling in Obesity
肥胖中炎症信号传导与亚硝基化信号传导的未折叠蛋白反应的整合
  • 批准号:
    10062953
  • 财政年份:
    2017
  • 资助金额:
    $ 49.74万
  • 项目类别:

相似海外基金

Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8358448
  • 财政年份:
    2012
  • 资助金额:
    $ 49.74万
  • 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8517552
  • 财政年份:
    2012
  • 资助金额:
    $ 49.74万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7952159
  • 财政年份:
    2009
  • 资助金额:
    $ 49.74万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7952152
  • 财政年份:
    2009
  • 资助金额:
    $ 49.74万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7719194
  • 财政年份:
    2008
  • 资助金额:
    $ 49.74万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7605416
  • 财政年份:
    2007
  • 资助金额:
    $ 49.74万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7605425
  • 财政年份:
    2007
  • 资助金额:
    $ 49.74万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7378753
  • 财政年份:
    2006
  • 资助金额:
    $ 49.74万
  • 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
  • 批准号:
    6825160
  • 财政年份:
    2004
  • 资助金额:
    $ 49.74万
  • 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
  • 批准号:
    2702283
  • 财政年份:
    1997
  • 资助金额:
    $ 49.74万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了